Cullinan Associates Inc. Has $9.81 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Share on StockTwits

Cullinan Associates Inc. increased its stake in Pfizer Inc. (NYSE:PFE) by 1.2% during the fourth quarter, Holdings Channel.com reports. The fund owned 250,489 shares of the biopharmaceutical company’s stock after buying an additional 2,887 shares during the period. Cullinan Associates Inc.’s holdings in Pfizer were worth $9,814,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. AE Wealth Management LLC lifted its stake in shares of Pfizer by 19.7% in the fourth quarter. AE Wealth Management LLC now owns 249,525 shares of the biopharmaceutical company’s stock worth $9,776,000 after acquiring an additional 41,038 shares during the period. Investors Asset Management of Georgia Inc. GA ADV lifted its stake in Pfizer by 0.5% in the fourth quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 54,129 shares of the biopharmaceutical company’s stock valued at $2,121,000 after buying an additional 250 shares during the period. Farmers Trust Co. lifted its stake in Pfizer by 0.4% in the fourth quarter. Farmers Trust Co. now owns 177,566 shares of the biopharmaceutical company’s stock valued at $6,957,000 after buying an additional 690 shares during the period. Wedge Capital Management L L P NC lifted its stake in Pfizer by 8,853.8% in the fourth quarter. Wedge Capital Management L L P NC now owns 1,061,826 shares of the biopharmaceutical company’s stock valued at $41,602,000 after buying an additional 1,049,967 shares during the period. Finally, New England Professional Planning Group Inc. acquired a new position in Pfizer in the fourth quarter valued at approximately $9,160,000. 70.21% of the stock is currently owned by institutional investors.

Shares of NYSE:PFE opened at $40.67 on Thursday. The company has a quick ratio of 0.68, a current ratio of 0.90 and a debt-to-equity ratio of 0.55. Pfizer Inc. has a twelve month low of $33.97 and a twelve month high of $44.56. The stock’s 50 day moving average is $38.90 and its 200-day moving average is $38.18. The firm has a market capitalization of $221.75 billion, a price-to-earnings ratio of 13.56, a PEG ratio of 4.24 and a beta of 0.65.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.13. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. The company had revenue of $12.68 billion for the quarter, compared to analyst estimates of $12.37 billion. During the same period in the prior year, the firm earned $0.78 earnings per share. Pfizer’s revenue for the quarter was down 4.6% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 2.97 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 31st will be given a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a dividend yield of 3.74%. This is a positive change from Pfizer’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, January 30th. Pfizer’s dividend payout ratio is presently 48.00%.

Several equities analysts have issued reports on the company. Royal Bank of Canada assumed coverage on Pfizer in a research note on Monday, January 6th. They issued an “outperform” rating and a $46.00 price target on the stock. Credit Suisse Group reissued a “hold” rating and issued a $41.30 price target on shares of Pfizer in a research note on Wednesday, November 6th. Bank of America assumed coverage on Pfizer in a research note on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 price target on the stock. Zacks Investment Research raised Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target on the stock in a research note on Tuesday, October 1st. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Pfizer in a research note on Tuesday, October 29th. Nine research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $43.41.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: Are analyst ratings accurate?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.